Your browser doesn't support javascript.
loading
Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.
van de Velde, Helgi; Londhe, Anil; Ataman, Ozlem; Johns, Helen L; Hill, Stephen; Landers, Emma; Berlin, Jesse A.
Afiliação
  • van de Velde H; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Londhe A; Janssen Research and Development, Horsham, PA, USA.
  • Ataman O; Janssen Research & Development, High Wycombe, UK.
  • Johns HL; FireKite, an Ashfield Company, part of UDG Healthcare plc, Maidenhead, UK.
  • Hill S; FireKite, an Ashfield Company, part of UDG Healthcare plc, Maidenhead, UK.
  • Landers E; FireKite, an Ashfield Company, part of UDG Healthcare plc, Maidenhead, UK.
  • Berlin JA; Johnson & Johnson, Titusville, NJ, USA.
Eur J Haematol ; 98(3): 269-279, 2017 Mar.
Article em En | MEDLINE | ID: mdl-27859769
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Idioma: En Ano de publicação: 2017 Tipo de documento: Article